Compare RBCAA & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RBCAA | PHAR |
|---|---|---|
| Founded | 1974 | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | 1998 | 2020 |
| Metric | RBCAA | PHAR |
|---|---|---|
| Price | $76.44 | $16.46 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | N/A | ★ $38.33 |
| AVG Volume (30 Days) | ★ 69.7K | 8.0K |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.40% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.77 | N/A |
| Revenue | ★ $417,495,000.00 | N/A |
| Revenue This Year | $3.93 | $10.04 |
| Revenue Next Year | N/A | $2.51 |
| P/E Ratio | ★ $97.52 | $3,041.22 |
| Revenue Growth | ★ 8.50 | N/A |
| 52 Week Low | $63.97 | $8.39 |
| 52 Week High | $78.00 | $21.34 |
| Indicator | RBCAA | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 59.37 | 45.92 |
| Support Level | $66.20 | $16.35 |
| Resistance Level | $76.74 | $17.49 |
| Average True Range (ATR) | 2.37 | 0.47 |
| MACD | 0.11 | -0.10 |
| Stochastic Oscillator | 85.28 | 2.50 |
Republic Bancorp Inc operates as a financial institution that provides both traditional and non-traditional banking products through five reportable segments. It has traditional banking, which generates the majority of revenue, Warehouse Lending, Tax Refund Solutions (TRS), Republic Payment Solutions segment, and Republic Credit Solutions (RCS) business segments. The business activities of these segments include retail mortgage and commercial lending, construction and land development lending, internet lending, correspondent and indirect lending, and also private banking, treasury management services, internet, and mobile banking, bank acquisitions, short-term revolving credit facilities, fixed-term residential real estate loans, and receipt and payment of federal.
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.